Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kobayashi, S. Hirose, A. Murata, N. Morishita, T. Kitagawa, Y. Ohtsuki (Kochi, Matusyama, Japan). Differences in the immunolocalization of surfactant protein (SP)-A, SP-D and KL-6 in pulmonary alveolar proteinosis. Eur Respir J 2008; 32: Suppl. 52, 252

Member's Comments

No comment yet.

Related content which might interest you: Surfactant proteins in pulmonary alveolar proteinosis in adults Source: Eur Respir J 2004; 24: 426-435 Year: 2004 Abnormal intraalveolar accumulation of surfactant proteins in adults with pulmonary alveolar proteinosis Source: Eur Respir J 2002; 20: Suppl. 38, 90s Year: 2002 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Surfactant dysfunction and alveolar proteinosis Source: ERS Skills Course 2016 Year: 2016 Surfactant dysfunction and alveolar proteinosis Source: ERS Course 2019 - Summer school of paediatric respiratory medicine 2019 Year: 2019 Surfactant dysfunction and alveolar proteinosis Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017 Surfactant dysfunction and alveolar proteinosis Source: ERS Course 2018 - Summer school of paediatric respiratory medicine Year: 2018 Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis Source: Eur Respir J 2008; 31: 1197-1204 Year: 2008 Our cases with pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 The benefits of whole lung lavage in pulmonary alveolar proteinosis Source: Eur Respir J 2004; 23: 503-505 Year: 2004 Pulmonary alveolar proteinosis and GM/CSF antibodies Source: Eur Respir J 2005; 26: Suppl. 49, 30s Year: 2005 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Pulmonary alveolar proteinosis Source: Eur Respir Mon; 2009: 46: 208–224 Year: 2009 Pulmonary alveolar proteinosis Source: Eur Respir Rev 2011; 20: 98-107 Year: 2011 PAS-negative pulmonary alveolar proteinosis Source: Annual Congress 2008 - Rare clinical cases Year: 2008